Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162636 | 0.91 | ALDH1A1 (0.48) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL8408330 | 0.85 | L3MBTL1 (0.55) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL15842178 | 0.85 | ESR1 (0.54) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL15956090 | 0.85 | TSHR (0.50) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL23189019 | 0.85 | TSHR (0.50) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL159881 | 0.84 | CYP1A2 (0.51) | TSHRCYP1A2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL5700005 | 0.84 | SMN1; SMN2 (0.50) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL5700280 | 0.84 | L3MBTL1 (0.52) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL5700217 | 0.84 | ESR1 (0.50) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL2360263 | 0.81 | TSHR (0.50) | TSHRCYP1A2CYP2C19CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | TSHR 4862/4885CYP1A2 4010/4885CYP2C19 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.